> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Xofigo
- URL: https://www.fdaweb.com/review-period-set-for-xofigo/
- Published: 2016-06-21T12:00:00.000Z
- Updated: 2026-09-14T21:11:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136009

*Federal Register* Notice: FDA has determined the regulatory review period for Xofigo is 1,945 days for extending a patent which claims the human drug product. FDA has approved for marketing the human drug product Xofigo (radium 223 dichloride) for treating patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-06-21/pdf/2016-14551.pdf?ref=fdaweb.com).